ESSA Pharma (NASDAQ:EPIX) Stock Passes Below 50 Day Moving Average of $8.94

Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $8.94 and traded as low as $7.75. ESSA Pharma shares last traded at $7.76, with a volume of 16,906 shares trading hands.

ESSA Pharma Trading Down 5.9 %

The company has a market cap of $343.30 million, a PE ratio of -13.15 and a beta of 1.62. The business has a fifty day simple moving average of $8.94 and a two-hundred day simple moving average of $6.83.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last posted its quarterly earnings results on Tuesday, February 13th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities analysts expect that ESSA Pharma Inc. will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in shares of ESSA Pharma by 41.7% in the first quarter. Bank of America Corp DE now owns 11,614 shares of the company’s stock valued at $72,000 after purchasing an additional 3,420 shares during the last quarter. Swiss National Bank increased its stake in shares of ESSA Pharma by 7.5% in the 1st quarter. Swiss National Bank now owns 57,200 shares of the company’s stock worth $353,000 after acquiring an additional 4,000 shares during the last quarter. BNP Paribas Arbitrage SNC increased its stake in shares of ESSA Pharma by 52.8% in the 2nd quarter. BNP Paribas Arbitrage SNC now owns 14,405 shares of the company’s stock worth $39,000 after acquiring an additional 4,976 shares during the last quarter. Rock Springs Capital Management LP raised its holdings in shares of ESSA Pharma by 2.1% during the 3rd quarter. Rock Springs Capital Management LP now owns 677,005 shares of the company’s stock worth $2,092,000 after acquiring an additional 13,688 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of ESSA Pharma by 62.5% during the 2nd quarter. Jane Street Group LLC now owns 40,421 shares of the company’s stock valued at $127,000 after acquiring an additional 15,548 shares during the last quarter. 75.12% of the stock is owned by hedge funds and other institutional investors.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.